Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Gartisertib (Primary) ; Niraparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
Most Recent Events
- 06 Jun 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Dec 2022 Planned End Date changed from 1 Dec 2027 to 1 May 2027.
- 28 Dec 2022 Planned primary completion date changed from 1 Dec 2023 to 1 May 2024.